List of Blueprint priority diseases
2018 annual review of the Blueprint list of priority diseases
For the purposes of the R&D Blueprint, WHO has developed a special tool for determining which diseases and pathogens to prioritize for research and development in public health emergency contexts. This tool seeks to identify those diseases that pose a public health risk because of their epidemic potential and for which there are no, or insufficient, countermeasures. The diseases identified through this process are the focus of the work of R& D Blueprint. This is not an exhaustive list, nor does it indicate the most likely causes of the next epidemic.
The first list of prioritized diseases was released in December 2015.
Using a published prioritization methodology, the list was first reviewed in January 2017.
The second annual review occurred 6-7 February, 2018. Experts consider that given their potential to cause a public health emergency and the absence of efficacious drugs and/or vaccines, there is an urgent need for accelerated research and development for*:
Crimean-Congo haemorrhagic fever (CCHF)
Ebola virus disease and Marburg virus disease
Lassa fever
Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS)
Nipah and henipaviral diseases
Rift Valley fever (RVF)
Zika
Disease X
Disease X represents the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease, and so the R&D Blueprint explicitly seeks to enable cross-cutting R&D preparedness that is also relevant for an unknown “Disease X” as far as possible.
という具合にツーヒットのネタは尽きない。
2018 annual review of the Blueprint list of priority diseases
For the purposes of the R&D Blueprint, WHO has developed a special tool for determining which diseases and pathogens to prioritize for research and development in public health emergency contexts. This tool seeks to identify those diseases that pose a public health risk because of their epidemic potential and for which there are no, or insufficient, countermeasures. The diseases identified through this process are the focus of the work of R& D Blueprint. This is not an exhaustive list, nor does it indicate the most likely causes of the next epidemic.
The first list of prioritized diseases was released in December 2015.
Using a published prioritization methodology, the list was first reviewed in January 2017.
The second annual review occurred 6-7 February, 2018. Experts consider that given their potential to cause a public health emergency and the absence of efficacious drugs and/or vaccines, there is an urgent need for accelerated research and development for*:
Crimean-Congo haemorrhagic fever (CCHF)
Ebola virus disease and Marburg virus disease
Lassa fever
Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS)
Nipah and henipaviral diseases
Rift Valley fever (RVF)
Zika
Disease X
Disease X represents the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease, and so the R&D Blueprint explicitly seeks to enable cross-cutting R&D preparedness that is also relevant for an unknown “Disease X” as far as possible.
という具合にツーヒットのネタは尽きない。
